{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:40:56Z","timestamp":1773420056001,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T00:00:00Z","timestamp":1416355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Clinical studies have shown that interventional lowering of serum free thyroxine (FT4) may be associated with extended survival in patients with some terminal cancers. The report of success with this approach in glioblastoma multiforme caused involvement of the author (A.H.) in the prospective consultative management of 23 end-stage solid tumor patients in whom hypothyroxinemia was induced to prolong life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>Patients were self-referred or recommended by attending physicians to the author (A.H.) and had advanced cancers of the brain, ovary, lung, pancreas, salivary gland, and breast or had mesothelioma or soft-tissue sarcoma. Hypothyroxinemia was achieved in euthyroid patients by using methimazole, with the addition of 3,3\u2032,5-triiodo-l-thyronine (l-T3) to prevent hypothyroidism and suppress endogenous thyrotropin (TSH). In patients with pre-existent primary hypothyroidism, T3 administration was substituted for T4 replacement. Serum FT4 and TSH concentrations were serially monitored to enable adjustments to drug therapy and prevent clinical hypothyroidism. Survival was measured from the date of hypothyroxinemia induction with T3 or methimazole plus T3. Outcomes were compared with the odds of death based on the Surveillance Epidemiology and End Results and American Joint Committee on Cancer databases and literature reports.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>The survival time of 83% (19 of 23) of patients exceeded the 20% expected 1-year survival for this hypothyroxinemic, end-stage cancer group. The difference between actual and expected survival was significant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Although this is an uncontrolled observational experience with frank limitations, compassionate medical induction of hypothyroxinemia should be considered for patients with advanced cancers to whom other avenues of treatment are closed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0308","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T07:27:54Z","timestamp":1416468474000},"page":"72-76","source":"Crossref","is-referenced-by-count":76,"title":["Medically Induced Euthyroid Hypothyroxinemia May Extend Survival in Compassionate Need Cancer Patients: An Observational Study"],"prefix":"10.1093","volume":"20","author":[{"given":"Aleck","family":"Hercbergs","sequence":"first","affiliation":[{"name":"Departments of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Neuroradiology, Cleveland Clinic, Cleveland, Ohio, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osnat","family":"Ashur-Fabian","sequence":"additional","affiliation":[{"name":"Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Garfield","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center, Aurora, Colorado, USA;"},{"name":"ProMed Cancer Centers, Shanghai, People's Republic of China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Albany Medical College, Albany, New York, USA;"},{"name":"The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,11,19]]},"reference":[{"key":"2021122309083111600_B1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/er.2009-0007","article-title":"Molecular aspects of thyroid hormone actions","volume":"31","author":"Cheng","year":"2010","journal-title":"Endocr Rev"},{"key":"2021122309083111600_B2","first-page":"245","article-title":"The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia\u2014a novel paradigm","volume":"10","author":"Hercbergs","year":"1996","journal-title":"In Vivo"},{"key":"2021122309083111600_B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pharmtox-010510-100512","article-title":"Membrane receptor for thyroid hormone: Physiologic and pharmacologic implications","volume":"51","author":"Davis","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2021122309083111600_B4","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/ERC-12-0219","article-title":"Thyroid hormone, thyroid hormone receptors, and cancer: A clinical perspective","volume":"20","author":"Moeller","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2021122309083111600_B5","first-page":"617","article-title":"Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: A phase I\/II study","volume":"23","author":"Hercbergs","year":"2003","journal-title":"Anticancer Res"},{"key":"2021122309083111600_B6","article-title":"Early onset propylthiouracil induced hypothyroidism is associated with improved survival in recurrent high grade glioma [abstract 1211]","volume-title":"Presented at: American Association of Cancer Research annual meeting","author":"Hercbergs","year":"2008"},{"key":"2021122309083111600_B7","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1210\/en.2005-0102","article-title":"Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis","volume":"146","author":"Bergh","year":"2005","journal-title":"Endocrinology"},{"key":"2021122309083111600_B8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.vph.2009.10.007","article-title":"Thyroid hormone and angiogenesis","volume":"52","author":"Luidens","year":"2010","journal-title":"Vascul Pharmacol"},{"key":"2021122309083111600_B9","doi-asserted-by":"crossref","first-page":"C980","DOI":"10.1152\/ajpcell.00305.2008","article-title":"L-Thyroxine vs. 3,5,3\u2032-triiodo-L-thyronine and cell proliferation: Activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase","volume":"296","author":"Lin","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"2021122309083111600_B10","first-page":"337","article-title":"Identification and functions of the plasma membrane receptor for thyroid hormone analogues","volume":"11","author":"Lin","year":"2011","journal-title":"Discov Med"},{"key":"2021122309083111600_B11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CAD.0b013e32835c7a47","article-title":"Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: A case report and review of the literature","volume":"24","author":"Ashur-Fabian","year":"2013","journal-title":"Anticancer Drugs"},{"key":"2021122309083111600_B12","volume-title":"SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988\u20132001, Patient and Tumor Characteristics","author":"Ries","year":"2007"},{"key":"2021122309083111600_B13","volume-title":"AJCC Cancer Staging Manual,","author":"Edge","year":"2007","edition":"7th ed."},{"key":"2021122309083111600_B14","volume-title":"Nonparametric and Shortcut Statistics in the Social, Biological, and Medical Sciences","author":"Tate","year":"1957"},{"key":"2021122309083111600_B15","volume-title":"RECIST: Response Evaluation Criteria in Solid Tumors"},{"key":"2021122309083111600_B16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MED.0b013e32833d9710","article-title":"Thyroid hormones and cancer: Clinical studies of hypothyroidism in oncology","volume":"17","author":"Hercbergs","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2021122309083111600_B17","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1158\/0008-5472.CAN-05-4365","article-title":"Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells","volume":"66","author":"Davis","year":"2006","journal-title":"Cancer Res"},{"key":"2021122309083111600_B18","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.4161\/cc.8.21.9963","article-title":"Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)","volume":"8","author":"Glinskii","year":"2009","journal-title":"Cell Cycle"},{"key":"2021122309083111600_B19","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1210\/jc.2009-1926","article-title":"Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid","volume":"95","author":"Yalcin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122309083111600_B20","first-page":"1575","article-title":"Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate","volume":"62","author":"Shoemaker","year":"1979","journal-title":"J Natl Cancer Inst"},{"key":"2021122309083111600_B21","first-page":"3515","article-title":"Enhancing effect of thyroxine on tumor growth and metastases in syngeneic mouse tumor systems","volume":"39","author":"Kumar","year":"1979","journal-title":"Cancer Res"},{"key":"2021122309083111600_B22","first-page":"3040","article-title":"Inhibition of local and metastatic hepatoma growth and prolongation of survival after induction of hypothyroidism","volume":"41","author":"Mishkin","year":"1981","journal-title":"Cancer Res"},{"key":"2021122309083111600_B23","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1596::AID-CNCR30>3.0.CO;2-C","article-title":"Propylthiouracil-induced hypothyroidism reduces xenograft tumor growth in athymic nude mice","volume":"86","author":"Theodossiou","year":"1999","journal-title":"Cancer"},{"key":"2021122309083111600_B24","doi-asserted-by":"crossref","first-page":"e27547","DOI":"10.1371\/journal.pone.0027547","article-title":"Crosstalk between integrin \u03b1v\u03b23 and estrogen receptor-\u03b1 is involved in thyroid hormone-induced proliferation in human lung carcinoma cells","volume":"6","author":"Meng","year":"2011","journal-title":"PLoS One"},{"key":"2021122309083111600_B25","first-page":"25","article-title":"Effects of experimental hyper- and hypothyroidism on natural defense activities against Lewis lung carcinoma and its spontaneous pulmonary metastases in C57BL\/6 mice","volume":"38","author":"Kinoshita","year":"1991","journal-title":"Tokushima J Exp Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0308","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/1\/72\/41867249\/oncolo_20_1_72.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/1\/72\/41867249\/oncolo_20_1_72.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:13:25Z","timestamp":1640312005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/1\/72\/6399261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,19]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,11,19]]},"published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0308","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,1,1]]},"published":{"date-parts":[[2014,11,19]]}}}